Merck Serono (Switzerland)

Recent papers from Merck Serono (Switzerland)

1. Human prostaglandin reductases dearomatize and inactivate benzothiazinone antitubercular drugsEMBO Molecular Medicine · 2026
2. Language of Toxicity: An eXplainable Artificial Intelligence ApproachJournal of Chemical Information and Modeling · 2026
3. Persistence and adherence to tepotinib in patients with metastatic non-small cell lung cancer: a real-world evidence study including dose reductionsFuture Oncology · 2026
4. M5542, a bifunctional fusion protein targeting CD80, CD86, and OX40L that modulates excessive T-cell activity: a preclinical proof-of-concept studyFrontiers in Immunology · 2026
5. Elevating the Patient Voice in Early Phase Oncology Drug Development: The Value of Patient‐Reported Outcomes in Dosage Optimization Leveraging Clinical Pharmacology PrinciplesClinical Pharmacology & Therapeutics · 2026
6. A General Workflow for Tangential Flow Filtration Perfusion Scale‐UpBiotechnology and Bioengineering · 2026
7. Incorporating estimands into meta-analyses of clinical trialsResearch Synthesis Methods · 2026
8. Managing the patient with hypertension and elevated heart rate in the routine care setting: expert opinion and narrative reviewCurrent Medical Research and Opinion · 2026
9. A multi-outcome prognostic score for therapeutic responses in multiple sclerosisRevue Neurologique · 2026
10. Safety, pharmacokinetics, and antimalarial efficacy of single-dose cabamiquine–pyronaridine combination therapy for the treatment of adults and adolescents with acute uncomplicated Plasmodium falciparum malaria (CAPTURE 1): a prospective, multicentre, open-label, phase 2a studyThe Lancet Infectious Diseases · 2026
11. A Qualitative Study of Lived Treatment Experiences and Preferences of Long-Term DMT Users with Relapsing–Remitting Multiple SclerosisNeurology and Therapy · 2026
12. Effect of pimicotinib on tumor response and physical function (PF) by tumor location in patients with tenosynovial giant cell tumor (TGCT): Results from the phase 3 MANEUVER trial.Journal of Clinical Oncology · 2026
13. Longer-term safety of pimicotinib in tenosynovial giant cell tumor (TGCT): Integrated analysis of phase 1 and phase 3 MANEUVER trial data.Journal of Clinical Oncology · 2026
14. Adverse events and their management in patients with tenosynovial giant cell tumor (TGCT) treated with pimicotinib, after longer-term follow-up from the global phase 3 MANEUVER trial.Journal of Clinical Oncology · 2026
15. QSAR in the AI Era: Reflections for Advancing Chemical Safety AssessmentChemical Research in Toxicology · 2026
16. PRIMUS: a precision medicine platform reusing clinical trials and registry data to support treatment selection in multiple sclerosisJAMIA Open · 2026
17. First-in-human study of the dual A2A/A2B adenosine receptor antagonist muvadenant (M1069) in patients with advanced solid tumorsESMO Open · 2026
18. Enpatoran, a Toll-like receptor 7/8 inhibitor, in moderate-to-severe systemic lupus erythematosus: findings from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trialThe Lancet · 2026
19. Abstract Number: Esoc2026a1168 Health-Related Quality of Life Outcomes in Patients With Acute Ischaemic Stroke (AIs) Treated With Aptoll 0.2 Mg/Kg in the April Phase 1b/2a StudyEuropean Stroke Journal · 2026
20. Updated systematic literature review and network meta-analysis of cladribine tablets versus currently approved disease-modifying treatments for active relapsing-remitting multiple sclerosisMultiple Sclerosis and Related Disorders · 2026